Allscripts Announces Second Quarter of 2022 Results
Veradigm Inc. (MDRX)
Last veradigm inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.allscripts.com
Company Research
Source: Business Wire
Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021Generated $42 million of cash flow from continuing operations in the quarter CHICAGO--(BUSINESS WIRE)--Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2022.Second quarter 2022 Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021. On a consolidated Allscripts basis second quarter 2022 revenue was $151 million compared with $141 million in the second quarter of 2021.In the second quarter, Allscripts completed the sale of its Hospital and Large Physician Practices Segment. The transaction had significant impacts on the GAAP based income statement for the quarter as we recorded significant transaction costs in operations, and a very large tax provision reflecting the difference between the book and tax basis of the assets sold. These non-recurring items
Show less
Read more
Impact Snapshot
Event Time:
MDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDRX alerts
High impacting Veradigm Inc. news events
Weekly update
A roundup of the hottest topics
MDRX
News
- Update in Lawsuit for Investors who purchased shares of Veradigm Inc. (NASDAQ: MDRX) announced by the Shareholders FoundationPR Newswire
- Veradigm Inc. (NASDAQ: MDRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Veradigm Inc. (NASDAQ: MDRX) had its "hold" rating re-affirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $10.00 price target on the stock, down previously from $15.00.MarketBeat
- Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor ForumBusiness Wire
- Veradigm Inc. (NASDAQ: MDRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
MDRX
Sec Filings
- 3/15/24 - Form 4/A
- 3/15/24 - Form 3/A
- 3/13/24 - Form 8-K
- MDRX's page on the SEC website